Current Therapy for Metastatic Urothelial Carcinoma

被引:5
作者
Nadal, Rosa [1 ]
Clara, Joseph A. [1 ]
Valderrama, Begona P. [2 ]
Bellmunt, Joaquim [3 ]
机构
[1] NHLBI, Cellular & Mol Therapeut Branch, NIH, 10 Ctr Dr,Room 3E-5330, Bethesda, MD 20892 USA
[2] Hosp Univ Virgen Rocio, Ave Manuel Siurot S-N, Seville 41001, Spain
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med Oncol, 330 Brookline Ave,KS 118, Boston, MA 02215 USA
关键词
Urothelial carcinoma; Systemic therapy; Immune checkpoint inhibitors; Targeted therapy; FGFR inhibitor; Antibody-drug conjugate; TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; GEMCITABINE PLUS CISPLATIN; COLONY-STIMULATING FACTOR; RANDOMIZED-TRIAL; OPEN-LABEL; 1ST-LINE CHEMOTHERAPY; DOUBLE-BLIND; COMBINATION CHEMOTHERAPY; WEEKLY PACLITAXEL;
D O I
10.1016/j.hoc.2021.02.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:469 / 493
页数:25
相关论文
共 126 条
[1]   Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 [J].
Alva, A. ;
Csoszi, T. ;
Ozguroglu, M. ;
Matsubara, N. ;
Geczi, L. ;
Cheng, S. Y-S. ;
Fradet, Y. ;
Oudard, S. ;
Vulsteke, C. ;
Morales Barrera, R. ;
Flechon, A. ;
Gunduz, S. ;
Loriot, Y. ;
Rodriguez-Vida, A. ;
Mamtani, R. ;
Yu, E. Y. ;
Nam, K. ;
Imai, K. ;
Moreno, B. H. ;
Powles, T. B. .
ANNALS OF ONCOLOGY, 2020, 31 :S1155-S1155
[2]  
[Anonymous], FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis
[3]   Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors [J].
Apolo, Andrea B. ;
Nadal, Rosa ;
Girardi, Daniel M. ;
Niglio, Scot A. ;
Ley, Lisa ;
Cordes, Lisa M. ;
Steinberg, Seth M. ;
Sierra Ortiz, Olena ;
Cadena, Jacqueline ;
Diaz, Carlos ;
Mallek, Marissa ;
Davarpanah, Nicole N. ;
Costello, Rene ;
Trepel, Jane B. ;
Lee, Min-Jung ;
Merino, Maria J. ;
Bagheri, Mohammad Hadi ;
Monk, Paul ;
Figg, William D. ;
Gulley, James L. ;
Agarwal, Piyush K. ;
Valera, Vladimir ;
Chalfin, Heather J. ;
Jones, Jennifer ;
Streicher, Howard ;
Wright, John J. ;
Ning, Yangmin M. ;
Parnes, Howard L. ;
Dahut, William L. ;
Bottaro, Donald P. ;
Lara, Primo N., Jr. ;
Saraiya, Biren ;
Pal, Sumanta K. ;
Stein, Mark N. ;
Mortazavi, Amir .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) :3672-+
[4]   Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial [J].
Apolo, Andrea B. ;
Nadal, Rosa ;
Tomita, Yusuke ;
Davarpanah, Nicole N. ;
Cordes, Lisa M. ;
Steinberg, Seth M. ;
Cao, Liang ;
Parnes, Howard L. ;
Costello, Rene ;
Merino, Maria J. ;
Folio, Les R. ;
Lindenberg, Liza ;
Raffeld, Mark ;
Lin, Jeffrey ;
Lee, Min-Jung ;
Lee, Sunmin ;
Alarcon, Sylvia V. ;
Yuno, Akira ;
Dawson, Nancy A. ;
Allette, Kimaada ;
Roy, Arpita ;
De Silva, Dinuka ;
Lee, Molly M. ;
Sissung, Tristan M. ;
Figg, William D. ;
Agarwal, Piyush K. ;
Wright, John J. ;
Ning, Yangmin M. ;
Gulley, James L. ;
Dahut, William L. ;
Bottaro, Donald P. ;
Trepel, Jane B. .
LANCET ONCOLOGY, 2020, 21 (08) :1099-1109
[5]   Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].
Apolo, Andrea B. ;
Infante, Jeffrey R. ;
Balmanoukian, Ani ;
Patel, Manish R. ;
Wang, Ding ;
Kelly, Karen ;
Mega, Anthony E. ;
Britten, Carolyn D. ;
Ravaud, Alain ;
Mita, Alain C. ;
Safran, Howard ;
Stinchcombe, Thomas E. ;
Srdanov, Marko ;
Gelb, Arnold B. ;
Schlichting, Michael ;
Chin, Kevin ;
Gulley, James L. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+
[6]   First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].
Balar, Arjun V. ;
Castellano, Daniel ;
O'Donnell, Peter H. ;
Grivas, Petros ;
Vuky, Jacqueline ;
Powles, Thomas ;
Plimack, Elizabeth R. ;
Hahn, Noah M. ;
de Wit, Ronald ;
Pang, Lei ;
Savage, Mary J. ;
Perini, Rodolfo F. ;
Keefe, Stephen M. ;
Bajorin, Dean ;
Bellmunt, Joaquim .
LANCET ONCOLOGY, 2017, 18 (11) :1483-1492
[7]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[8]   Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Aravantinos, G ;
Deliveliotis, C ;
Bafaloukos, D ;
Kalofonos, C ;
Xiros, N ;
Zervas, A ;
Mitropoulos, D ;
Samantas, E ;
Pectasides, D ;
Papakostas, P ;
Gika, D ;
Kourousis, C ;
Koutras, A ;
Papadimitriou, C ;
Bamias, C ;
Kosmidis, P ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :220-228
[9]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[10]   The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation [J].
Bardhan, Kankana ;
Anagnostou, Theodora ;
Boussiotis, Vassiliki A. .
FRONTIERS IN IMMUNOLOGY, 2016, 7